TransMedics (TMDX) Current Deferred Revenue (2018 - 2025)
TransMedics has reported Current Deferred Revenue over the past 8 years, most recently at $2.9 million for Q4 2025.
- Quarterly results put Current Deferred Revenue at $2.9 million for Q4 2025, up 66.76% from a year ago — trailing twelve months through Dec 2025 was $2.9 million (up 66.76% YoY), and the annual figure for FY2025 was $2.9 million, up 66.76%.
- Current Deferred Revenue for Q4 2025 was $2.9 million at TransMedics, down from $3.3 million in the prior quarter.
- Over the last five years, Current Deferred Revenue for TMDX hit a ceiling of $3.3 million in Q3 2025 and a floor of $152000.0 in Q3 2021.
- Median Current Deferred Revenue over the past 5 years was $960000.0 (2021), compared with a mean of $1.2 million.
- Biggest five-year swings in Current Deferred Revenue: tumbled 49.68% in 2022 and later surged 1063.27% in 2023.
- TransMedics' Current Deferred Revenue stood at $250000.0 in 2021, then decreased by 3.6% to $241000.0 in 2022, then skyrocketed by 713.69% to $2.0 million in 2023, then dropped by 11.17% to $1.7 million in 2024, then skyrocketed by 66.76% to $2.9 million in 2025.
- The last three reported values for Current Deferred Revenue were $2.9 million (Q4 2025), $3.3 million (Q3 2025), and $1.6 million (Q2 2025) per Business Quant data.